Press Release December 14, 2020

Relay Therapeutics Announces Collaboration and License Agreement with Genentech for RLY-1971

The Life Sciences team advised Relay Therapeutics, Inc. (Nasdaq: RLAY) on its collaboration and license agreement with Genentech, a member of the Roche Group, for the development and commercialization of RLY-1971, a potent inhibitor of SHP2. Under the collaboration, Genentech will assume development of RLY-1971 with the potential to expand into multiple combination studies including with Genentech’s investigational inhibitor of KRAS G12C, GDC-6036.

Relay Therapeutics is a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion.

Under the terms of the agreement, Relay Therapeutics will receive $75 million upfront and is eligible to receive an additional $25 million in near-term payments and up to $695 million in additional potential milestones, plus royalties on product sales.

The Goodwin team was led by Kathleen Kean and Yasee Zahedi and included Kingsley Taft, Daniel Karelitz, Bill Collins, Theresa Kavanaugh, Gaby Morales-Rivera, Jason Goldfarb, Taylor Harrison, Alex Varond, and Paul Jin

For more details, read the press release and articles in Endpoints, FierceBiotech, and BioSpace.